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The Academic Research Consortium (ARC)-2 initiative revisited the clinical and angiographic end point definitions in coronary device tri-
als, proposed in 2007, to make them more suitable for use in clinical trials that include increasingly complex lesion and patient populations
and incorporate novel devices such as bioresorbable vascular scaffolds. In addition, recommendations for the incorporation of patient-
related outcomes in clinical trials are proposed. Academic Research Consortium-2 is a collaborative effort between academic research
organizations in the United States and Europe, device manufacturers, and European, US, and Asian regulatory bodies. Several in-person
meetings were held to discuss the changes that have occurred in the device landscape and in clinical trials and regulatory pathways in the
last decade. The consensus-based end point definitions in this document are endorsed by the stakeholders of this document and strongly
advocated for clinical trial purposes. This Academic Research Consortium-2 document provides further standardization of end point defi-
nitions for coronary device trials, incorporating advances in technology and knowledge. Their use will aid interpretation of trial outcomes
and comparison among studies, thus facilitating the evaluation of the safety and effectiveness of these devices.
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..Since the first Academic Research Consortium (ARC) recommen-
dations on standardized end point definitions in coronary device
investigations, the landscape of coronary intervention has consid-
erably evolved.1 The technology has matured, and more-comer
populations with more complex lesions are a major focus of clinic-
al trials. Physiology-guided percutaneous coronary intervention
(PCI) has been incorporated into clinical practice guidelines.2
Bioresorbable vascular scaffolds (BRS) have been introduced that
have unique failure modes compared with predicate devices. In
addition, the universal definition of Myocardial Infarction (MI) was
updated in 20123,4 (with a further revision due in 2018), and the
Society for Cardiovascular Angiography and Interventions (SCAI)
proposed a common definition of “clinically relevant MI” for
periprocedural PCI– and coronary artery bypass graft (CABG)–
related events that have been shown to have prognostic signifi-
cance.5 Finally, PCI and CABG trials have generally focused on
reporting treatment failures (death, MI, and reintervention) as a
measure of efficacy. The relatively low frequency of these events
with contemporary drug-eluting stents (DES) makes demonstrat-
ing differences between current devices difficult and misses an op-
portunity to assess the impact of revascularization on other
measures of patient status such as patient-centered outcomes
that may affect larger numbers of patients.
The ARC definitions have been widely used in clinical and research
settings and have provided a standard for consistency in reporting
clinical outcomes that has been replicated by subsequent ARC initia-
tives. The current initiative reconsidered the end point definitions in
device studies to make them more suitable to the present and future
needs of clinical trials in more complex settings. Table 1 shows the
salient differences between ARC-1 and ARC-2 in terms of the defini-
tions of end points common to both documents.
Similar to the ARC-1 process, in-person meetings involving ARC
study group members, independent experts, including surgeons and
interventional cardiologists, the US Food and Drug Administration,
and industry representatives provided much of the substantive dis-
cussion from which this ARC-2 consensus document was derived





The basis for coronary device evaluation should be overall cardiovas-
cular outcomes from the patient perspective, including death, MI,
stroke, and repeat revascularization procedures, but may also con-
sider myocardial ischemia and objective, validated measures of quality
of life (Figure 1 and Table 2).
Composite End Points
The ARC-2 consensus suggests the composite end points for device
trials listed in Table 2. Composites generated by the combination of
individual end points provide additional statistical power to detect
potentially meaningful differences between treatments. The individual
components should represent clinically meaningful events, should be
linked by common elements of pathophysiology, and should be
reported individually.
....................................................................................................................................................................................................................
Table 1 Salient Differences Between ARC-1 and ARC-2 in Terms of the Definitions of End Points
End Point ARC-1 ARC-2 Additional Comments
Death (see also Table 3) 3 Categories: cardiac, vascular, and
noncardiovascular
3 Categories: cardiovascular, noncar-
diovascular, and undetermined
ARC-2 recommends subclassifica-
tion using CDISC criteria
Myocardial infarction
(see also Table 4)
(1) Different definitions of PMI for
PCI and CABG
(2) PMI criteria considered cTn/
CK-MB
(1) A single definition for both PCI
and CABG trials
(2) PMI incorporates hs-cTn
Specific ancillary angiographic and
imaging criteria are provided
(Table 5)
Repeat revascularization
(see also Tables 6 and 7)
Addressed only simple lesion
scenarios
Designed to accommodate all-
comer–based clinical trials and
complex anatomy
ARC-2 prioritizes functional evalu-
ation for adjudication of repeated
revascularizations as clinically indi-
cated (Table 7)
Stent thrombosis
(see also Tables 6 and 7)
(1) Considered only stent trials
(2) 3 Categories: definite, probable,
and possible
(1) Considers stent and BRS
studies
(2) 2 Categories: definite and
probable
ARC-2 incorporates definitions for
silent occlusion and intraproce-
dural device thrombosis
Patient-reported outcomes Not included Detailed description, including blind-
ing, quality control, handling of
missing data, frequency of assess-
ments, and duration of clinical
trials
ARC indicates Academic Research Consortium; BRS, bioresorbable scaffold; CABG, coronary artery bypass grafting surgery; CDISC, Clinical Data Interchange Standards
Consortium; CK-MB, creatine kinase-MB; cTn, cardiac troponin; hs-cTn, high-sensitivity cardiac troponin; MI, myocardial infarction; PCI, percutaneous coronary intervention;
and PMI, periprocedural myocardial infarction.








































Other composites such as net clinical benefit that may incorporate
safety-related events like bleeding or composites that include poten-
tial surrogate measures of device success such as patient-reported or
patient-centered outcomes might have application for specific devi-
ces and clinical trials. Similarly, additional end points such as any reho-
spitalization either for a cardiac reason (eg, unstable angina) or for a
reason related to the procedure may have application in specific tri-
als. The ARC-2 consensus for DES and BRS end points is, in most
cases, to regard such composites as secondary end points. We sug-
gest that the terms severe recurrent ischemia and urgent target ves-
sel revascularization, proposed as end points for some trials, be
avoided, although they may serve as Clinical Events Committee
(CEC) triggers to aid complete ascertainment of MI or repeat PCI.
Proposed Safety And Efficacy End
Points
Death
ARC-2 considers all-cause mortality the most unbiased method to re-
port deaths in a clinical trial or observational study, although it may be
less device or procedure specific than deaths adjudicated as cardiac in
origin (Table 3). Previously, ARC-1 recommended that death be
reported as cardiac and vascular. ARC-2 proposes that the cardiac and
vascular categories be merged into a single entity, cardiovascular, in
order to be consistent with pharmacological studies, although in individ-
ual trials, it may be reasonable to denote more specific subcategories.
Device trials are designed primarily to reduce cardiac morbidity
and mortality; thus, including noncardiac death may mask any poten-
tial signal of a device effect. Careful consideration of inclusion and ex-
clusion criteria for specific device trials has evident merit in this
context. However, we also recommend that a specific subcategory,
undetermined cause, be reported for deaths for which no informa-
tion is available. Deaths of undetermined cause will default to cardio-
vascular (but should be reported as a separate subcategory of
cardiovascular death to denote this uncertainty). Deaths related to
the procedure or complications of the procedure (or concomitant
treatment) are always classified as cardiovascular. Adjudication issues
are discussed in Appendix B in the online-only Data Supplement.
We further recommend that cardiovascular and noncardiovascu-
lar deaths be reported in tables in broad subcategories reflecting
commonly occurring causes of cardiovascular and noncardiovascular
Figure 1 Combined end points for clinical trials in coronary interventions. cTn, cardiac troponin; URL, upper reference limit.































..death, based on the Cardiovascular Endpoints Data Standards classifi-
cation,6 as outlined in Table 3.
Myocardial Infarction
MI may be an entry criterion for a clinical DES/BRS trial, may occur in
the periprocedural period, or may occur long after device implant-
ation as a result of spontaneous MI or late complications of the study
device.7,8
MI definitions include certain arbitrary assumptions and vary across
PCI, CABG, structural, and cardiovascular drug trials. In particular,
clinical trial definitions of periprocedural (type 4a) MI have been diffi-
cult to standardize. The complexity stems from the use of increasing-
ly sensitive biomarkers of subtle myocardial injury balanced against a
need to identify events that clearly affect clinical outcomes, including
mortality. Inconsistency among definitions remains a formidable bar-
rier to the understanding of results across clinical trials or the pooling
of results for the detection of safety signals. Variability comes from
the choice of different biomarkers (eg, creatine kinase-MB [CK-MB]
versus cardiac troponin [cTn]), the use of different ratios for individ-
ual biomarkers, and the adoption of different thresholds (eg, manu-
facturer upper reference limit [URL] versus site-determined upper
limit of normal) for adjudication.
The use of CK-MB versus cTn has been especially controversial
in the classification of periprocedural MI. On the basis of a wealth
of historical data, the SCAI suggested a CK-MB threshold of 10
times the upper limit of normal (or 5 times in the presence of new
Q waves) as a determinant of clinically relevant MI.5 In the last 2
decades, however, cTn has progressively replaced CK-MB as the
preferred biomarker of myocardial injury in all other clinical set-
tings. Thus, CK-MB assays are no longer available at many centers.
Both the added clinical value of cTn assays in the triage of patients
with suspected acute coronary syndrome and the prognostic
.................................................................................................
Table 3 Classification of Death
Type of Death Definition
Cardiovascular
death
Cardiovascular death is defined as death
resulting from cardiovascular causes. The
following categories may be collected:
1. Death caused by acute MI
2. Death caused by sudden cardiac, including
unwitnessed, death
3. Death resulting from heart failure
4. Death caused by stroke
5. Death caused by cardiovascular procedures
6. Death resulting from cardiovascular
hemorrhage




Noncardiovascular death is defined as any
death that is not thought to be the result of
a cardiovascular cause. The following cate-
gories may be collected:
1. Death resulting from malignancy
2. Death resulting from pulmonary causes
3. Death caused by infection (includes sepsis)
4. Death resulting from gastrointestinal causes
5. Death resulting from accident/trauma
6. Death caused by other noncardiovascular
organ failure
7. Death resulting from other noncardiovas-
cular cause
Undetermined Undetermined cause of death is defined as a
death not attributable to any other cat-
egory because of the absence of any rele-
vant source documents. Such deaths will
be classified as cardiovascular for end point
determination.
MI indicates myocardial infarction.
.................................................................................................
Table 2 Composite End Points












MI (not clearly attributable to a nontarget
vessel)
TLR (clinically driven)









Target vessel revascularization (clinically
driven)
TLR (clinically driven)
Any hospitalization either for a cardiac rea-
son or related to the procedure (and
concomitant treatment)












ARC indicates Academic Research Consortium; BARC, Bleeding Academic
Research Consortium; MI, myocardial infarction; and TLR, target lesion
revascularization.








































implications of background cTn levels regardless of the clinical set-
ting are clearly established.
However, cTn assays pose several challenges from a clinical trial
perspective. The analytic sensitivity among marketed cTn assays
varies over several orders of magnitude. Therefore, the absolute val-
ues from 1 assay are not interchangeable with those from another.
Furthermore, a several-fold increase (eg, 5 URL) with a high-
sensitivity cTn (hs-cTn) assay may not be associated with a detectable
increase with a less sensitive earlier-generation assay, leading to sig-
nificant differences in the event frequency based solely on the assay
used.
The term high sensitivity reflects the characteristics of the assay,
not a difference in the form of measured cTn. Specific criteria
have been proposed by the International Federation of Clinical
Chemistry and Laboratory Medicine to define hs-cTn assays.9
Briefly, such assays should detect measurable levels of cTn in
many (>50%) normal subjects and reliably detect changes (total
imprecision, ie, percent coefficient of variation <10%) at the 99th
percentile URL.
Spontaneous MI
ARC-2 endorses the classification of spontaneous MI and MI related
to complications of the study device (types 1, 2, 3, 4b, and 4c) pro-
posed by the 2012 universal definition of MI. We note that it can be
difficult for an event committee to distinguish type 1 MI from type 2
MI or nonischemic myocardial injury with necrosis when additional
investigations that might provide further clarification were judged in-
appropriate from a clinical perspective or when complete source
documentation is missing. ARC-2 recommends that suspected spon-
taneous MI triggers, for which a biomarker rise is documented with-
out clear evidence of a type 1 or 2 MI, should be adjudicated and
reported as “myocardial injury not meeting MI criteria” in clinical tri-
als. As noted, the use of multiple cTn assays in a trial, such as may
occur when different assays are used in referring and study centers, is
problematic. Adjudication issues are discussed in Appendix B in the
online-only Data Supplement.
Periprocedural PCI and CABG MI or Significant
Myocardial Injury
A threshold of significance for postprocedural cTn elevation has not
been determined for periprocedural MI. The initial common 2007
ARC and universal definition of periprocedural MI proposed a very
low (>3 URL) biomarker threshold for PCI with a preference for cTn
and did not require ancillary criteria. The ARC noted its concern that
the >3 cTn stand-alone threshold would be overly sensitive as a dis-
criminator of clinically meaningful differences among devices and rec-
ommended collection, in parallel, of CK-MB data. These concerns
were validated, and the subsequent 2012 universal definition of MI
both increased the cTn threshold and required additional criteria
(1 or more of the following: ischemic chest pain, angiographic compli-
cations, or imaging evidence of new loss of myocardium) for PCI-
related MI.
On the basis of the recognition that CK-MB data are less com-
monly available, there have been efforts to correlate cTn
elevations with CK-MB values and clinical outcomes.10 Although
the correlations are imperfect, the SCAI authors suggested an al-
ternative of cTn (>_70 the local laboratory upper limit of normal)
as a replacement for CK-MB (>_10 the local laboratory upper limit
of normal) on the basis of these calculations. Finally, the SCAI spe-
cifically excluded the use of hs-cTn assays for the cTn threshold
because of the absence of data. Analytical data have demonstrated
that at higher levels (100–10 000 ng/L), values obtained with the
fifth-generation hs-cTnT assay are highly correlated with values
obtained with the fourth-generation assay. As a result of the
greater precision of the hs-cTnT assay, there are significant differ-
ences at low (<100 ng/L) levels.11
The ARC acknowledges that CK-MB data will be available only in
certain situations such as when a central laboratory is funded by the
clinical investigation. Recognizing that cTn or hs-cTn has or will be-
come the standard, we propose alternative thresholds that approxi-
mate the CK-MB historical evidence. We acknowledge that, for
specific comparisons, the SCAI CK-MB, the 2012 universal definition
of MI, and/or the 2007 ARC-based thresholds may still be incorpo-
rated in ongoing trials. This includes those for which historical com-
parisons are critical or for specific trial designs such as comparisons
Comment Box
• ARC proposes a definition of periprocedural MI for PCI and
CABG with a common time frame, an identical biomarker thresh-
old, and clearly defined ancillary criteria.
• ARC recommends that MI triggers be adjudicated with the use of
the manufacturer-recommended URL (with sex-specific values
when relevant) to facilitate comparisons between trials.
• Ideally, a single cTn assay should be used, but if not feasible, the
use of the same cTn assay for the assessment of serial changes in
individual trial subjects is critically important. Only cTn assays that
comply with the minimum requirements of the 2012 universal def-
inition of MI are acceptable.
• Systematic assessment of serial (timing assay specific, generally 3–6
hours) cTn values, before intervention, to ascertain whether the
baseline levels are less than URL, elevated and stable or falling, or
elevated and potentially rising is critical both for MI adjudication
and for subsequent stratified analyses in clinical trials. In most PCI
trials, cTn may be measured when informed consent is obtained
and at the start of the procedure (eg, after arterial sheath place-
ment but before intervention).
• Given the potential for ascertainment bias, we strongly advocate
that the percentage of patients in whom biomarkers were actually
measured at protocol-mandated time points before and after the
procedure be reported in all trials and considered as a quality
metric.
• Hs-cTn values must be reported as whole numbers in nanograms
per liter as recommended by the International Federation of
Clinical Chemistry and Laboratory Medicine.
• All data for cTn and CK-MB should be tabulated for each classifi-
cation to include at least the following multiples of the URL by
treatment groups: >1, >_5, >_10, >_35, >_70, >_100, and >_250.
Cumulative frequency distributions for cTn and CK-MB by treat-
ment group should be provided.


















































..between PCI and CABG. However, when this is the case, we recom-
mend that the ARC-2 definitions, described below, also be reported.
On the basis of the CK-MB historical evidence, ARC-2 proposes a
common >_35 URL threshold for cTn for both PCI- and CABG-
related periprocedural MI as a reasonable threshold (Table 4). This
absolute rise applies both to patients with baseline cTn levels <URL
and to those in whom baseline cTn levels are elevated and stable or
falling. The ARC is concerned that the 20% rise compared with base-
line, proposed by the Universal Definition Taskforce in patients with
elevated and stable or falling cTn levels at baseline, may be overly sen-
sitive in those with modest and insufficiently sensitive in those with
marked elevation in baseline cTn for use as a discriminator in clinical
trials.
ARC proposes that 1 ancillary criterion be required in addition
to the >_35 cTn rise to fulfill the definition of periprocedural MI.
The ancillary criteria are 1 or more of the following: “flow-limiting”
angiographic complications in a major epicardial vessel or >1.5-mm-
diameter branch, new significant Q waves (or equivalent) related to
the procedure, or a “substantial” new wall motion abnormality on
echocardiography related to the procedure. The ancillary angiograph-
ic and electrocardiographic criteria should be adjudicated, ideally after
core laboratory assessment, by an independent CEC. The CEC should
review the angiographic images and the 12-lead electrocardiographic
tracings (Table 5). Chest pain is not considered a criterion with suffi-
cient specificity to be a useful discriminator in this setting.
While acknowledging that no evidence-based prognostic thresh-
old for periprocedural injury exists for hs-cTn, we accept a rise in
cTn >_70 times the URL (when baseline levels are less than the URL
or elevated and stable or falling) as a reasonable threshold for a
stand-alone definition of significant periprocedural injury. We recom-
mend that these isolated biomarker elevations also be reported.
Although a perfect definition is not possible, this allows discrimination
between therapies such as novel DES or scaffolds at a level that is
Table 4 Periprocedural Myocardial Infarction
Percutaneous Coronary Intervention and Coronary
Artery Bypass Grafting (Within 48 Hours)
Myocardial infarction
Absolute rise in cardiac troponin (from baseline) >_35 times upper
reference limit
Plus 1 (or more) of the following criteria
New significant* Q waves or equivalent
Flow-limiting angiographic complications
New “substantial” loss of myocardium on imaging
Significant periprocedural myocardial injury
Absolute rise in cardiac troponin (from baseline) >_70 times upper
reference limit
Definitions applicable in patients with normal (or elevated and stable or falling)
baseline biomarkers. For specific trials, the Society for Cardiovascular
Angiography and Interventions, the 2012 universal definition of myocardial infarc-
tion, or the 2007 Academic Research Consortium criteria may be preferred.
When this is the case, we recommend the Academic Research Consortium-2 cri-
teria also be reported.
*Q-wave criteria requires the development of new Q waves >_40 ms in duration
and >_1 mm deep in voltage in >_2 contiguous leads.
....................................................................................................................................................................................................................
Table 5 Angiographic Complications/Imaging Criteria
Complications Criteria
Loss of patency of major vessel,
graft, or side branch
Abrupt main vessel closure
1. When TIMI grade 3 or 2 flow at baseline; TIMI grade 0 or 1 flow after the procedure
2. When TIMI grade 1 flow at baseline; TIMI grade 0 flow after the procedure
3. When TIMI grade 0 flow at baseline and vessel patency (TIMI grade 2 or 3 flow) established during
procedure; TIMI grade 0 flow after procedure
Side branch (>_1.5 mm) occlusion after the procedure: TIMI grade 0 or 1 flow in a side branch initially
patent with TIMI grade 2 or 3 flow
Embolization The appearance of an abrupt cutoff in the distal vessel (or in a side branch >_1.5 mm) after percutan-
eous coronary intervention
Disruption of collateral flow Reduction in collateral flow by >_1 grades (Rentrop classification)
Persistent slow flow or no reflow Markedly delayed flow (TIMI grade 2 for slow flow, TIMI 0 or 1 for no reflow) in a target vessel with
minimal (<30%) residual stenosis at the stented/scaffolded segment and no evidence of flow-limit-
ing dissection
Major dissection Dissection in the target vessel greater than type B from National Heart, Lung, and Blood Institute
classification
Coronary artery bypass graft surgery specific Angiographically documented new occlusion or flow-limiting stenosis in the graft or new native cor-
onary artery occlusion
New regional wall motion abnormality Ideally, prospectively predefined imaging protocol or, in its absence, core laboratory or CEC
adjudicated
Imaging evidence of loss of viable myocardium Ideally, prospectively predefined imaging protocol or, in its absence, core laboratory or CEC
adjudicated
CEC indicates Clinical Events Committee; and TIMI, Thrombolysis in Myocardial Infarction.






































potentially meaningful. For completeness, we strongly urge complete
reporting of biomarker data at various thresholds for a qualitative
comparison.
A recent American College of Cardiology/American Heart
Association consensus document states:
When data elements and definitions are standardized across
studies, comparison, pooled analysis, and meta-analysis are
enabled, thus deepening our understanding of individual studies.
Although end point definitions may evolve over time, a period in
which definitions remain static is needed for terms to be used
successfully to conduct a meta-analysis.6
The ARC recognizes that the advent of hs-cTn assays with precise-
ly defined, objective, and reproducible parameters for the various
elements of the definition could serve as a benchmark to provide the
data set for such a meta-analysis.
When the baseline cTn is elevated and rising or when a second de-
termination is superfluous (eg, ST-segment–elevation MI), the ARC
considers that it is not possible to reliably distinguish whether a sub-
sequent biomarker rise results from the index MI or is a new MI
related to a periprocedural complication. Research protocols in such
populations may adopt study-specific end points such as those pro-
posed by SCAI to adjudicate events related to the procedure that
may inform a future revision of this document.
Silent MI
The term silent MI, as defined by the Universal Definition Taskforce,
refers to new significant Q waves that develop during follow-up out-
side the periprocedural period. ARC-2 suggests that such events be
reported as a separate end point, typically not as a component of the
primary end point, in the absence of a clinical event with documented
biomarker elevation. ARC-2 suggests that the same Q-wave criteria
(development of new Q waves >_40 ms in duration and >_1 mm deep
in voltage in >_2 contiguous leads) as for PMI may be used.
Alternatively, the methodology used to detect silent MI should be
prespecified in detail in the protocol.
Regulatory Considerations
For a study intended for review by a regulatory authority, sponsors
may propose a periprocedural MI definition for the primary analysis
that is most appropriate for the trial design. This is of particular rele-
vance for studies that use historical control data, taking into account
the definition used in the control data sets. Although the universal
definition of MI and SCAI periprocedural MI definitions have advan-
tages and limitations, ARC acknowledges that they are reasonable,
and we suggest, when possible, an additional analysis of periproce-
dural MI rates with alternative definitions used as a secondary end
point to assess the consistency of study outcomes. It is recom-
mended that the selected definition be discussed with regulators be-
fore the initiation of patient enrollment. Regardless of the
periprocedural MI definition, the most important issue in the assess-
ment of periprocedural events is a complete as possible ascertain-
ment of the necessary data (ie, measurement of cardiac biomarkers
and ancillary clinical criteria).
MI Adjudication in the Absence of Minimum Prespecified
Protocol Data
As noted above, the failure to measure protocol-specified criteria,
generally biomarker levels, may result in underreporting and
....................................................................................................................................................................................................................
Table 6 Repeat Revascularization
Classification Definition
Target lesion The target lesion is defined as the treated segment including the 5-mm margin proximal and distal to the stent/scaffold.*
Target lesion revascularization Target lesion revascularization is defined as a repeat percutaneous intervention of the target lesion or bypass
surgery of the target vessel performed for restenosis or other complication of the target lesion.
Target vessel The target vessel is defined as the entire major intervened coronary vessel, including side branches.
Target vessel revascularization Target vessel revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment
of the target vessel including the target lesion.
Target vessel non–target lesion
revascularization
Target vessel non-target lesion revascularization is defined as any repeat percutaneous intervention or surgical
bypass of the target vessel for pre-existing disease, disease progression or other reasons unrelated to the target
lesion as defined above.
*The Clinical Events Committee may ask for the help of a quantitative coronary analysis core laboratory for the identification of target lesion and adjudication of TLR.
Table 7 Fractional Flow Reserve and Quantitative
Coronary Analysis for Event Adjudication of Clinically
Indicated Repeat Revascularizations
Hierarchically
1. Core laboratory–reported fractional flow reserve <_0.80 or instant
wave-free ratio <_0.89
2. Site-reported fractional flow reserve <_0.80 or instant wave-free
ratio <_0.89
3. Quantitative coronary analysis* diameter stenosis >50% (based on
the average of multiple views) with either recurrent symptoms or
positive noninvasive functional test
4. Quantitative coronary analysis* diameter stenosis >70% (based on
the average of multiple views) regardless of other criteria
5. Quantitative coronary analysis diameter stenosis >70% (based on
the worst view) regardless of other criteria
*Three-dimensional analysis is preferred when available.




























































































potentially introduce bias. Ideally, such scenarios should be addressed
upfront in the protocol and CEC charter. However, this is often not
the case. We propose (Appendices B and C in the online-only Data
Supplement) broadly applicable criteria for CEC adjudication when
specific elements for periprocedural or spontaneous MI are perman-
ently missing.
Stroke
Although stroke is rare in the context of coronary device trials, it is
an important periprocedural complication of CABG and may occur
during follow-up after either revascularization strategy. The ARC rec-
ommends that the recent NeuroARC classification be followed.12
Central to these recommendations are the need for assessment at
the investigational site by an independent neurologist and the inclu-
sion in the CEC membership of a neurologist to advise on all or
selected potential stroke and transient ischemic event triggers as pre-
defined in the CEC charter.
Bleeding
The ARC recommends that bleeding complications in PCI or CABG
trials be classified according to the Bleeding Academic Research
Consortium criteria.13
Repeat Revascularization
Target lesion revascularization is defined as reintervention for clinic-
ally significant renarrowing and thus includes 2 fundamental factors: a
functional component and a clinical component (Table 6). The defin-
ition of clinically indicated target lesion revascularization (TLR) or
target vessel revascularization was an integral part of the 2007
ARC document. We noted that a prerequisite to designate a reinter-
vention as clinically indicated or ischemia driven was the demonstra-
tion of a 50% to 70% stenosis on quantitative coronary angiography
(QCA) at the target lesion or in the target vessel, assessed by an inde-
pendent core laboratory (with additional criteria as defined in
Table 7). These criteria, incorporating the role of an independent
core laboratory using quantitative methods for assessment, are an in-
dustry standard that is widely accepted by investigators, trial spon-
sors, and regulatory authorities around the world. The field has
evolved, and the current ARC consensus gives priority to functional
assessment with fractional flow reserve (FFR) or equivalent techni-
ques. However, CEC adjudication, with the aid of independent QCA
assessment of baseline and reintervention angiograms at a minimum,
is mandatory when functional assessments are not performed in trials
in which TLR or target vessel revascularization is an end point
(Table 6). Of note, in PCI versus CABG trials, the ascertainment of
target lesion revascularization is challenging, if not impossible, in the
CABG arm. Therefore, ARC recommends that only target vessel
revascularization is considered in such trials.
On occasion, at the index procedure, attempted study stent im-
plantation may prove unsuccessful because of technical (eg, failure to
predilate a calcified lesion) or other (eg, periprocedural unanticipated
hemodynamic instability) challenges, and the patient is brought back
later for a second attempt. In such situations, following the intention-
to-treat principle, the second procedure should be considered a
target lesion revascularization unless otherwise specified in the
protocol. Thus, the time frame for repeat revascularization starts
from the moment the patient is taken off the catheterization labora-
tory table.
Physiological assessments (either FFR or instant wave-free ratio
[iFR]) may be useful to justify repeat revascularization procedures
as part of the clinical end point adjudication and may serve as a cri-
terion to validate the justification for intervention at the time of
study entry in specific protocols. Many lesions with <50% diam-
eter stenosis on QCA are FFR positive, and many with >50%
diameter stenosis are FFR negative, particularly if a single view is
used for QCA. In fact, a significant proportion of lesions visually
>70% stenotic are FFR negative.
The most important trial design concern with incorporating FFR/
iFR data into the end point adjudication process will be the assurance
of uniform ascertainment. The protocol must specify clearly which
suspect lesions should undergo FFR assessment. Suggested schemes
for trials with and without planned angiographic follow-up are pre-
sented in Figures 2 and 3.
The study protocol and CEC manual of operations must also
clearly outline, in advance, how FFR/iFR data will be incorporated
into the adjudication process in specific scenarios. We recommend
that when protocol-mandated FFR/iFR is not performed, such revas-
cularizations should be classified as clinically indicated. We further
recommend that when FFR results differ from the results of noninva-
sive testing or results on QCA, FFR/iFR should take precedence in
the decision-making hierarchy.
ARC-2 recommends that resting distal coronary pressure to aortic
pressure ratio, contrast/saline FFR, quantitative flow ratio, and FFR
from computed tomography, although not yet widely available, can,
within their acknowledged limitations, be used for adjudication pur-
poses if specified in the protocol. In the near future, perfusion-based
computed tomography may be validated as an additional technique
to guide event adjudication.
ARC-2 recognizes that all trial protocols may not incorporate the
mandatory use of FFR (or any other functional assessment). When
this is the case, we recommend the use of independent core
laboratory–verified QCA analysis using the hierarchical approach out-
lined in Table 7. These measurements, in conjunction with symptom
status and the results of noninvasive testing, will form the basis for
event adjudication. A report of the European Society of Cardiology–
European Association of Percutaneous Cardiovascular Interventions
Task Force on the Evaluation of Coronary Stents in Europe14
endorsed the role of independent QCA analysis, stating, “Offline
quantitative coronary analysis in a centralized core laboratory with
blinded outcome assessors in case of comparative studies is man-
datory.” Similarly, the US Food and Drug Administration15 emphasizes
the role of independent quantitative angiographic assessment.
The QCA analysis should be provided to the CEC team to assist
its assessment in conjunction with the clinical data with access to the
original angiograms on request.
ARC-2 recommends that all DES/BRS study designs require com-
pletion of clinical evaluations before any protocol-mandated invasive
procedures are performed. This approach will avoid the bias
observed in several studies in which an increase in TLR related to
protocol-mandated catheterization was documented.















































Staged procedures are frequently performed in complex multivessel
cases to decrease the risk of contrast-induced nephropathy and to in-
crease the likelihood of complete revascularization. All staged proce-
dures should be completed with the assigned study stent.
The decision to stage and the reason(s) along with the specific
lesions to be treated during the staged procedure should be docu-
mented at the end of the index procedure in the electronic case re-
port form. Latitude is allowed when the index procedure is
performed in an acute setting and the local heart team may guide sub-
sequent management. In studies in which chronic total occlusions are
index lesions, subsequent procedures may be undertaken to achieve
final angiographic success.
Planned documented staged procedures are not considered TLRs.
However, the recommended time interval within which planned
elective staged PCI procedures should be completed must be defined
in the protocol. When a staged procedure is performed earlier (or
later) than planned, it should be adjudicated, taking into account the
circumstances. For example, when a culprit lesion was treated at
index and a staged intervention is performed earlier than planned be-
cause of unscheduled readmission with symptoms, the procedure
should be classified as an unplanned PCI. When a staged procedure is
performed outside the time window for valid logistical or medical
reasons, it may be classified as a protocol violation and not an un-
planned PCI. However, when a decision was made that a planned
staged procedure was no longer indicated, subsequent treatment of
such lesions will be considered an unplanned PCI. All of these scen-
arios should be described in the protocol and CEC charter.
ARC-2 strongly recommends that staged procedures be allowed
only in vessels not treated at the index procedure to avoid potential
disruption of the index lesions.
Bifurcation Lesions
The Medina classification has gained general acceptance as a simple,
relevant clinical and research tool, and we recommend that dedi-
cated bifurcation trials adopt this classification. If another classification
is used, it should be prespecified in the protocol.
Core laboratory analysis using dedicated QCA bifurcation soft-
ware has documented that patients included in bifurcation trials often
have less complex disease compared with the visually assessed
parameters that led to inclusion in the trial. The ARC recommends
that criteria be verified before trial inclusion. If preprocedural inde-
pendent verification of inclusion criteria is not performed, a retro-
spective analysis (prespecified in the protocol) may provide
supplemental information to the intention-to-treat population. ARC-
2 recommends that in such a scenario, both per-protocol independ-
ent core laboratory–verified and intention-to-treat populations be
reported.
Other issues concerning the adjudication of revascularization are
discussed in Appendix B in the online-only Data Supplement.
Figure 2 Suggested template for trial design: planned angiographic follow-up. DS, diameter stenosis; eCRF, electronic case report form; FFR, frac-
tional flow reserve; iFR, instant wave-free ratio.




















































The first ARC document proposed a standardized classification based
on a consensus that both levels of evidence and timing of events
could be stratified to define varying degrees of certainty and to imply
different pathophysiological mechanisms. This classification required
evidence of a clinical event and did not include silent late occlusions
as manifestations of stent thrombosis. The time frame for stent
thrombosis starts when the patient has been undraped and taken off
the catheterization laboratory table (Table 8).
This classification included unexplained death within 30 days after
the procedure as a criterion for probable stent thrombosis. Given
the uncertain specificity of this criterion after ST-segment–elevation
MI, the updated ARC-2 classification recommends no longer includ-
ing unexplained death within 30 days as a criterion for probable stent
thrombosis when the index procedure was performed in the context
of ST-segment–elevation MI, albeit with evident implications for his-
torical comparisons.
In line with the nomenclature target lesion/vessel revascularization,
investigators may consider the term target lesion thrombosis to refer
to definite stent/scaffold thrombosis and target vessel thrombosis to
refer to probable stent/scaffold thrombosis. This new nomenclature
can accommodate late thrombotic events occurring in BRS studies
when is not certain whether the device is still present in the coronary
artery.
The initial ARC stent thrombosis classification included possible
stent thrombosis to capture potential stent thrombosis events occur-
ring beyond 1 year that may present as unexplained death. However,
it has become apparent that an increasing proportion of deaths
remain unexplained over time, leading to a potential exaggeration of
the rates of very late stent thrombosis and possible dilution of a signal
for differences between groups resulting from noise created by inclu-
sion of events unrelated to stent thrombosis. A recent autopsy study
suggested that the possible stent thrombosis category be refined,
through the use of additional criteria, to define a “modified possible”
stent thrombosis category that offered improved diagnostic accuracy
in this setting.16 ARC-2 feels that this modest improvement in diag-
nostic accuracy, however, does not justify its adoption and recom-
mends that the possible stent thrombosis category be removed
altogether (Table 7). Nevertheless, we emphasize again the import-
ance of careful clinical follow-up and complete ascertainment of clin-
ical data for the duration of any clinical study to minimize the
uncertainty in determining cause of death and thus to help identify
potential late or very late stent thrombosis events.
Reporting of late or very late stent thrombosis may be complex to
interpret when events occur secondary to an intervening TLR, but
censorship may bias reporting in favor of devices with higher resten-
osis risk. ARC-2 favors reporting of such events as secondary stent
thrombosis.
The initial ARC consensus considered that the incidental docu-
mentation of stent occlusion, without the required ancillary criteria,
should be classified as silent stent occlusion. While maintaining this
view, ARC-2 recommends that the numbers of such cases be
reported in studies in which angiographic follow-up is prespecified in
the protocol. Such reporting offers the potential to enhance
the understanding of the frequency and implications of this
phenomenon.
Figure 3 Suggested template for trial design: no planned angiographic follow-up. ACS, acute coronary syndrome; DS, diameter stenosis; eCRF,
electronic case report form; FFR, fractional flow reserve; iFR, instant wave-free ratio.





































..Intraprocedural stent thrombosis has been recognized for some
time, but a prognostic role for this rare event has only recently been
suggested. The definition is based on masked independent core la-
boratory frame-by-frame analysis of the angiogram.17,18 No studies
on variability among core laboratories have been reported.
Furthermore, such events may not be recorded on angiography, thus
raising the issue of ascertainment bias. ARC-2 recommends intrapro-
cedural stent thrombosis as an additional, optional classification but
does not include it as a subcategory of stent thrombosis, the timing of
which begins when the patient has been taken off the catheterization
laboratory table.
First-generation BRS platforms are now approved in many coun-
tries, and many novel platforms are undergoing clinical trials. ARC-2
recommends long-term follow-up, beyond the anticipated resorption
phase, to capture any potentially unexpected safety signals.
While acknowledging the semantic difficulty of classifying stent
thrombosis as being related to a BRS when resorption of the BRS is
theoretically complete, the ARC feels it is important to identify such
potential safety issues. The occurrence of definite stent thrombosis,
as defined in Table 8, within the 2 radiopaque markers or the 5-mm
proximal and distal margins will be regarded as scaffold site throm-
bosis. Stent thrombosis events, after BRS reintervention even years
after complete scaffold resorption, should also be reported as sec-
ondary stent thrombosis.
Bioresorbable Scaffolds
BRS are a novel technology based on polymeric or metallic platforms,
which have been developed to behave in a fashion similar to trad-
itional metallic DES in the short term but are then completely
resorbed over a variable time frame. The ARC recommends that, in
all such trials, patients should be followed up beyond the anticipated
bioresorption phase to capture any potentially unexpected safety
signals.
The lack of radiopacity of most BRS devices may be an issue when
the patient returns for protocol-mandated or clinically indicated angi-
ography. Acute unrecognized malapposition may result in scaffold
disruption during instrumentation of the vessel for protocol-
mandated invasive imaging. ARC-2 recommends that such TLRs in
....................................................................................................................................................................................................................




Angiographic confirmation of stent/scaffold thrombosis*
The presence of a thrombus† that originates in the stent/scaffold or in the segment 5 mm proximal or distal to the
stent/scaffold or in a side branch originating from the stented/scaffolded segment and the presence of at least 1 of
the following criteria:
Acute onset of ischemic symptoms at rest
New electrocardiographic changes suggestive of acute ischemia
Typical rise and fall in cardiac biomarkers (refer to definition of spontaneous myocardial infarction)
Or
Pathological confirmation of stent/scaffold thrombosis
Evidence of recent thrombus within the stent/scaffold determined at autopsy
Examination of tissue retrieved following thrombectomy (visual/histology)
Probable stent/scaffold
thrombosis
Regardless of the time after the index procedure, any myocardial infarction that is related to documented acute ische-
mia in the territory of the implanted stent/scaffold without angiographic confirmation of stent/scaffold thrombosis
and in the absence of any other obvious cause.‡
Silent stent/scaffold occlusion The incidental angiographic documentation of stent occlusion in the absence of clinical signs or symptoms is not
considered stent thrombosis.
Timing of ST (duration after stent implantation)
Acute 0§–24 h
Subacute >24 h–30 d
Late >30 d–1 y
Very late >1 y
Early stent thrombosis is 0 to 30 days (acute plus subacute stent thrombosis). MI indicates myocardial infarction.
*Definite stent/scaffold thrombosis is considered to have occurred by either angiographic or pathological confirmation.
†Occlusive thrombus: Thrombolysis in Myocardial Infarction grade 0 or 1 flow within or proximal to a stent/scaffold segment. Nonocclusive thrombus: intracoronary thrombus
is defined as a (spherical, ovoid, or irregular) noncalcified filling defect or lucency surrounded by contrast material (on 3 sides or within a coronary stenosis) seen in multiple
projections, persistence of contrast material within the lumen, or visible embolization of intraluminal material downstream.
‡When the stented/scaffolded segment is in the left circumflex coronary artery or in the presence of preexisting electrocardiographic abnormalities (eg, left bundle branch
block, paced rhythms), definitive evidence of localization may be absent and Clinical Events Committee adjudication is based on review of all available evidence).
§Defined as the moment the patient is undraped and taken off the catheterization table.




























































































..asymptomatic patients without restenosis be classified as nonclinically
indicated TLR.
Patient-reported Outcomes
Coronary device trials have generally considered treatment failure
(eg, target lesion failure) as the key parameter of efficacy and safety.
Although important, such outcomes are relatively rare. From the pa-
tient perspective, the key indications and benefits of coronary revas-
cularization often relate to improved health status measured in terms
of symptoms, function, and quality of life.19,20 Quantifying health sta-
tus is therefore a critical requirement for more completely defining
the benefits of treatment.21,22 Patient-reported outcomes systemat-
ically measure health status directly from the patient, without amend-
ment or interpretation of the response by a clinician or anyone else.
A patient-reported outcome can be captured by self-report or inter-
view, provided that the interviewer is trained to record only the
patient’s response. The outcome can be measured in absolute terms
(eg, severity of a symptom, sign, or state of a disease) or as a change
from a previous measure to more clearly define treatment benefit.
Although it is true that, in contemporary practice, fewer than 40%
of patients are treated with PCI for stable ischemic heart disease as
opposed to an acute coronary syndrome, all patients have coronary
artery disease. According to the guidelines, the principal goals of
treating patients with coronary disease are secondary prevention
(avoiding death and MI) and optimizing patients’ symptoms, function,
and quality of life. Among patients treated for acute MI or unstable
angina, a substantial proportion have angina and health status limita-
tions during follow-up, and baseline angina (angina before their acute
MI) is a strong predictor of longer-term angina.23 Accordingly, we
feel that the use of patient-reported outcomes should be routinely
considered in the design of clinical trials to provide important infor-
mation for subsequent medical decision making and shared medical
decision making with patients.
The US Food and Drug Administration has produced detailed
guidance on the use of patient-reported outcomes to make a claim
and to obtain product labeling.24 Generally, findings measured by a
well-defined and reliable patient-reported outcome instrument in ap-
propriately designed investigations can be used to support a claim in
medical product labeling if the claim is consistent with the docu-
mented measurement capability of the instrument. However, there
are certain challenges and requirements to accomplish patient-
reported outcome–based labeling, most notably the fact that no
patient-reported outcome has been qualified for the purpose of
labeling claims in coronary artery disease despite the availability of
well-validated measures.25–28 This represents a significant challenge
for researchers and industry in the quest to gain approval for treat-
ments that alleviate symptoms and improve function and quality
of life.
Assuming that a patient-reported outcome measure was qualified
by >_1 regulatory bodies, there are important considerations in
designing a trial to demonstrate treatment benefits from patients’
perspectives. If a patient-reported outcome is to be used as a trial
outcome, it is ideal to mask patients (and investigators performing
follow-up evaluations) to their randomized treatment to minimize
bias. Patient blinding is feasible in many device versus device studies
and is strongly recommended if possible. Patient blinding is rarely
feasible, however, in studies comparing strategies such as PCI and
medical or surgical treatment, with ORBITA (Objective Randomised
Blinded Investigation With Optimal Medical Therapy of Angioplasty
in Stable Angina) being a rare exception. In device versus device trials,
techniques that may minimize the effects of unblinding are useful. In
strategy trials, longer-term follow-up, during which patients’ percep-
tions of the immediate benefits of 1 treatment versus another (eg,
the placebo effect) may diminish, is important to show sustained
health status benefits over time. In open-label device trials, it is im-
portant to minimize bias by having patient-reported outcomes
administered by staff who are unaware of treatment assignment or
study hypotheses. Simple blinding and perception questionnaires may
be administered to evaluate the success of early and late patient
masking. Supplementing clinical trial data with future observational
registries can provide additional confidence in the benefits of therapy.
However, despite their importance to patients, it remains unclear
whether regulatory authorities will allow patient-reported outcomes
to be used as primary outcomes or if they will be relegated to only
secondary end points. In the current regulatory environment, we sug-
gest using patient-reported outcomes as supportive or secondary
end points unless discussions with the regulators indicate support for
their use as primary outcomes.
Regulatory qualification of a patient-reported outcome could sim-
plify selection of a measure to quantify the experiences of patients
with their disease and treatment. In the absence of guidance,
researchers need to select tools that will quantify the domains of
health most likely to be affected by treatment. Tool selection should
consider issues of sensitivity to clinical change, recall period, patient
burden (to minimize missing data), and the timing of patient-reported
outcome assessments. In general, disease-specific measures are much
more sensitive to treatment than generic tools.27 Any patient-
reported outcome instrument (eg, a questionnaire) to measure treat-
ment benefit or risk should have proven psychometric properties
(eg, validity, reliability, responsiveness, and interpretability) to meas-
ure the claimed concept.24 The recall period (ie, the time period
patients are asked to consider in response to a patient-reported out-
come item or questionnaire) can be momentary (real time) or retro-
spective and of varying length. In the setting of coronary disease, in
which angina typically occurs with exertion, recall periods are im-
portant so that patients can reflect on their recent symptoms across
a range of usual activities. It is important, however, to consider the
ability of patients to reliably recall the information requested.
Different instruments use different recall times. For example, the
Seattle Angina Questionnaire uses a 4-week recall period, which has
been shown to be highly correlated with patient-reported angina fre-
quency on daily diaries, thus suggesting that 4 weeks is not too long a
recall period for patients.25 Instruments vary in the number of ques-
tions they ask,29 and investigators need to explicitly consider what
domains of patient experience are most relevant in identifying the op-
timal measures while seeking to minimize the burden of data collec-
tion. At a minimum, patient-reported outcome assessments should
be administered before randomization and at a clinically relevant
follow-up interval. This not only ensures balanced randomization but
also enables absolute and relative changes in health status to be
















































..measured. Statistical analyses should explicitly describe how multiple
end points and missing data are handled and how the data will be ana-
lyzed to maximize interpretability of the results (eg, responder analy-
ses that can be converted in numbers needed to treat; Table 9).
In summary, a primary goal of coronary revascularization is to alle-
viate symptoms and functional limitations and to optimize quality of
life. Valid, sensitive, practical instruments exist to capture a range of
patients’ experiences. Clinical trial designs need to carefully consider
how alternative treatments might affect the health status of patients
and capture changes in these domains. Once available, these out-
comes can improve the understanding of treatment benefits and sup-
port the ability of doctors to communicate these benefits to their
patients.
Summary and Conclusions
The ARC-2 initiative has updated the widely used ARC-1 pragmat-
ic consensus definitions for coronary device trials to incorporate
experience gained with the initial definitions, interim recommen-
dations from professional societies, and the expansion of clinical
trials to include more complex patient/lesion subsets and novel
devices. Consistent application of these definitions in clinical trials
may result in more efficient regulatory evaluation. Consistent with
the ARC charter, this process and the definitions provided rely
heavily on consensus and highlight the role of key clinical trial
processes such as independent adjudication by event committees
and evaluation of angiographic outcomes by core laboratories.
In cases in which historical comparisons are important and for
specific study designs, we recommend reporting ARC-1 and -2
definitions, particularly with regard to death and stent/scaffold
thrombosis.
Recommendations for the integration of patient-reported out-
comes reflect the increasing focus on patient-centered outcomes in
addition to traditional hard clinical end points. The central priority
was the recognition that the application of consistent definitions
across clinical trials of devices or strategies for revascularization with
transparent reporting is ultimately more informative for the accrual
of knowledge than are multiple individual studies with varying, con-
tinually evolving definitions.
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Blinding Patients should (if feasible) be blinded to treatment assignment throughout the trial.
Investigators, research coordinators, and assistants during the follow-up period should be blinded throughout the trial.
A blinding or perception questionnaire at hospital discharge and at the time of the primary end point may be adminis-
tered to assess the success of patient blinding.
Quality control Training and instructions to patients for self-administered patient-reported outcome instruments.
Interviewer training and interview format for patient-reported outcome instruments administered in an interview
format.
Instructions for the clinical investigators for patient supervision, timing, and order of questionnaire administration during
or outside the office visit, processes and rules for questionnaire review for completeness, and documentation of
how and when data are filed, stored, and transmitted to or from the clinical trial site.
Plans for confirmation of the measurement properties of the instrument using clinical trial data.
Handling missing data Patients should remain in the clinical trial, even if they have discontinued treatment, and they should continue to pro-
vide patient-reported outcome data. The protocol should also establish a process by which patient-reported out-
come measurement is obtained before or shortly after patient withdrawal from treatment should early withdrawal
be unpreventable.
Frequency of assessments The timing of assessments should correspond to the specific research questions being addressed, the length of recall
asked by the response options of the instrument, demonstrated instrument measurement properties, the natural his-
tory of the disease or condition, the nature of the treatment, and planned data analysis.
Clinical trial duration Duration of follow-up with a patient-reported outcome assessment should be the same as for other measures of effect-
iveness. However, the clinical trial duration appropriate for the patient-reported outcomes–related objective may
not be the same duration as for other end points.
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